Siponimod Chips Away at Progressive MS.
Where this comes from
- Record sourced from PubMed, PMID 31951523.
- Also identified by DOI 10.1016/j.cell.2019.11.034 and PMC identifier 8023412.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Progressive multiple sclerosis (PMS) causes slow accumulation of neurologic disability and has been refractory to treatment with the immunomodulatory medications that effectively control relapsing MS. Siponimod modestly slowed the rate of disability progression among PMS patients who had inflammatory disease activity, evidenced by new or gadolinium-enhancing MRI lesions. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Azetidines
- Benzyl Compounds
- Clinical Trials as Topic
- Multiple Sclerosis